New hope for rare blood cancer: lenalidomide dose study shows promise

NCT ID NCT02302469

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug lenalidomide in 17 people with Waldenstrom macroglobulinemia, a rare blood cancer, that had returned or stopped responding to prior treatments. The main goal was to find the safest dose by monitoring side effects. Researchers also looked at how many patients responded to the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CH LENS

    Lens, 62307, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495, France

  • Centre Hospitalier de la côte basque

    Bayonne, 64109, France

  • Ch Clermond Ferrand

    Clermont-Ferrand, 63000, France

  • Ch Nantes

    Nantes, 44 093, France

  • Chru Lille

    Lille, 59037, France

  • Groupe hospitalier Pitié Salpétrière

    Paris, 75651, France